You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Patient-specific therapy of glioblastoma using lightly-labeled [14C]-temozolomide

    SBC: ACCIUM BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): It is widely accepted that the existing clinical paradigm of one treatment fits all is a major factor in the lack of progress in the effective treatment of a highly heterogeneous diseases. We propose a new innovative cl inical paradigm that optimizes brain cancer therapy using patient-specific markers of therapeutic response. Our long-term objective is to impro ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Optical nerve stimulation for a vestibular prosthesis

    SBC: Aculight Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Vestibular disorders represent a debilitating medical problem by causing balance and vision impairments that adversely affects the lives of people of all ages and backgrounds. The restoration of vestibular function by d irect stimulation of the vestibular nerve, bypassing the sensory organs, is expected to alleviate these symptoms in some patients. Currently, t ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. IMPROVED DIAGNOSTIC INFRARED NERVE STIMULATOR FOR ENT NERVE MONITORING

    SBC: Aculight Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Iatrogenic nerve damage is one of the most adverse sequalae of tumor resection surgery in all parts of the body. Many neuromonitoring techniques have been developed to lower the incidence of damage, most notably electr ostimulation. However, the clinical potential of precise neuromonitoring remains unfulfilled, due to several key limitations intrinsic to elect ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Nanoliter Lab-on-a-Chip for Rapid Parallel Immunoassays

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): The great need for more efficient and effective oncologic drug development has driven the discovery and integration of biomarkers into all phases of clinical research. Further still, biomarkers are entering the clinical arena as early means of determining which patients are likely benefiting from a particular drug. One field of targeted therapy that has relied ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Multiplexing Cancer Sample Preparation: Indirect Immunomagnetic Enrichment

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): Biomarkers of clinical activity are critical for targeted anti-cancer therapy development and are becoming important for the care of individual patients. In a prototypical tyrosine kinase pathway, governed by the epider mal growth factor receptor (EGFR), functional activity of the pathway is assessed by the phosphorylation status of EGFR and downstream signalin ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Improved Silicon Drift Detector Coincidence Rejection for Digital Pulse Processors

    SBC: 4pi Analysis, Inc.            Topic: N/A

    The recent emergence of the Silicon Drift detector (SDD), for use in Energy Dispersive x-ray Spectroscopy (EDS), has made possible x-ray event streams with input count rates in the range of 1-10 Mcps. Modern digital pulse processors are therefore required to run at fast time constants to achieve reasonable throughput; however, this causes significant coincidence artifacts to appear in the spectrum ...

    SBIR Phase I 2008 Department of CommerceNational Institute of Standards and Technology
  7. Peptide-Modified Sulfonated Styrene Block Copolymers for Vascular Applications

    SBC: AEGIS BIOSCIENCES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): A novel sulfonated polymer with unique chemically tailorable properties and processing characteristics has shown considerable promise as a thrombo- resistant surface and has been proven to be effective inhibitor against neutrophil- derived proteases. A phase 1 SBIR testing is proposed to investigate this polymer as a tailorable interface coating for blood-cont ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Localized Growth Factor Therapy for Surgical Hernia Repair

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. The incorporation of biocompatable mesh to strengthen the abdomi nal fascia has largely replaced high-tension suturing techniques in hernia repair. Currently, the preferred biomaterials include durable synthe ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Antibiotic-binding Peptides for Biofilm Prevention on Ventriculoperitoneal Shunts

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Ventriculoperitoneal (VP) shunts are used to treat pediatric and neonatal hydrocephalus in severe cases, representing approximately 1/3rd of affected infants. Due to the high susceptibility for infection and mechanica l breakdown, the failure rate of VP shunts is around 30-40%. A need therefore exists to improve infection prevention for this procedure, likely ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Tissue-targeted Antibiotics for the Prevention of Surgical Site Infection

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The Centers for Disease Control estimates that as many as 2 million people contract infections in hospitals each year, with as many as 100,000 deaths. Approximately 1/4 of hospital related infections (~500,000) are surg ical site infections. For each single patient, surgical site infections have been reported to require a median 6.5 additional days of hospital ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government